REGULATORY PANEL DISCUSSION: Navigating US FDA Import Enforcement: Avoiding Holds & Mastering the Border Pipeline 📊 LIVE POLL

  • How to format Global Import Documentation: Master FDA filing requirements for European and Chinese APIs and clinical materials to eliminate border holds caused by missing IND numbers, label mismatches, and improper valuation
  • How to resolve a notice of detention: Navigate the critical 30-day response window, coordinate with FDA investigators to fix errors, and avoid formal product refusals or trial delays
  • How to Protect US Pipelines from Global Friction: Secure US-bound supply chains against surging Chinese volumes by managing extended lead times, navigating fluctuating trade tariffs, and maintaining compliance through political shifts

CHINA SPOTLIGHT: Not Just a Drugmaker: How China is becoming the New World Leader in Clinical Trials

  • What accounts for China’s remarkable transition from pharmaceutical free rider to global innovator?
  • NRDL reform as the primary mechanism boosting China’s trials and drug development
  • How can the USA Clinical Trials Industry leverage local partnerships and smart planning to navigate the rapid growth of China’s R&D sector and unlock new opportunities for global success?
  • The importance of enhancing registry protocols and appropriate quality controls not only to ensure data accuracy and completeness but also foster global collaboration and transparency in clinical trials

Reserved for Global Data

🍻INTERACTIVE BEER BOARDROOM: COLLABORATE, SOLVE, SHARE 🤝

Many clinical supply chains treat Interactive Response Technology (IRT) as a passive transaction log rather than the strategic brain of their trial logistics. This disconnect routinely leads to rigid system setups, massive clinical waste, and exhausting, reactive “firefighting” when protocols inevitably shift.

In this interactive, live-case boardroom session, four IRT specialists will break down the invisible walls between system programming and physical supply chain management. Abandoning standard PowerPoint slides, our panel will guide the room through an interactive “Trial Autopsy” to map out the critical blind spots in the clinical lifecycle.

Key Takeaways & Interactive Themes:

  • Lost in Translation: How to actually communicate with your IRT vendor or internal specialists during setup so your supply rules don’t get butchered.
  • The “Just in Case” Trap: Why over-buffering your site stock creates a nightmare of waste, and how to let live data do the heavy lifting instead.
  • Playing Offense, Not Defense: Moving away from panicked, reactive fixes and configuring your IRT to spot bottlenecks weeks before a patient walks through the clinic door.

OPENING INTERACTIVE PANEL DISCUSSION: The Ethical AI Blueprint: Scaling Clinical Trials with Patient Safety First 📊 LIVE POLL

  • How the industry can align on responsible AI practices to guarantee end-to-end patient safety
  • Deconstructing the FDA/EMA joint AI Guidance: How to promote responsible innovation while maintaining rigorous regulatory standards
  • How do you actually implement AI within these strict frameworks without paralyzing your development cycles?
  • Purpose-Driven AI Governance: The Importance of defining a precise context of use for AI tools to guarantee regulatory compliance, robust validation and patient safety

FDA & EMA: Invited

CASE STUDY: Mastering the 6-4-2 Shift: A Supply Chain Roadmap to the 12-Digit NDC

  • How to identify where NDCs are hardcoded in your clinical packaging, labeling, and warehouse management systems
  • The Burden of Dual-Format Management: Strategies for handling the messy transition period where both 10 – and 12-digit codes will coexist in the market.
  • A step-by-step checklist to align regulatory, clinical operations, and IT partners for a seamless system overhaul

INDUSTRY CASE STUDY: Clinical Integrity in Transit: Safeguarding Global Supply Chain Quality

  • Navigating complex multi-country labeling requirements and implement proactive customs safeguards to prevent devastating temperature excursions during transit delays
  • Establishing risk-based validation protocols for global shipping routes before clinical trials begin, ensuring investigational product stability and effectiveness from start to finish
  • Implement strict “Chain of Condition” protocols, combining real-time data loggers to confidently release or quarantine clinical materials upon arrival

Vendor Opportunity